In
situ sensing of physiological and pathological species in cancer
cells is of great importance to unravel their molecular and cellular
processes. However, the biosensing with conventional probes is often
limited by the undesired on-target off-tumor interference. Here, we
report a novel strategy to design enzymatically controlled nanoflares
for sensing and imaging molecular targets in tumor cells. The triggerable
nanoflare was designed via rational engineering of structure-switching
aptamers with the incorporation of an enzyme-activatable site and
further conjugation on gold nanoparticles. The nanoflare sensors did
not respond to target molecules in normal cells, but they could be
catalytically activated by specific enzymes in cancer cells, thereby
enabling cancer-specific sensing and imaging in vitro and in vivo
with improved tumor specificity. Considering that diverse aptamers
were selected, we expect that this strategy would facilitate the precise
detection of a broad range of targets in tumors and may promote the
development of smart probes for cancer diagnosis.
With more and more new aptamers being reported, a general,
cost-effective
yet reliable aptamer binding assay is still needed. Herein, we studied
cationic conjugated polymer (CCP)-based binding assays taking advantage
of the conformational change of aptamer after binding with a target,
which is reflected by the fluorescence change of the CCP. Poly(3-(3′-N,N,N-triethylamino-1′-propyloxy)-4-methyl-2,5-thiophene
hydrochloride) (PMNT) was used as a model CCP in this study, and the
optimal buffer was close to physiological conditions with 100 mM NaCl
and 10 mM MgCl2. We characterized four aptamers for K+, adenosine, cortisol, and caffeine. For cortisol and caffeine,
the drop in the 580 nm peak intensity was used for quantification,
whereas for K+ and adenosine, the fluorescence ratio at
580 over 530 nm was used. The longer stem of the stem-loop structured
aptamer facilitated binding of the target and enlarged the detection
signal. High specificity was achieved in differentiating targets with
analogues. Compared with the SYBR Green I dye-based staining method,
our method achieved equal or even higher sensitivity. Therefore, this
assay is practicable as a general aptamer binding assay. The simple,
label-free, quick response, and cost-effective features will make
it a useful method to evaluate aptamer binding. At the same time,
this system can also serve as label-free biosensors for target detection.
Cationic conjugated polymers (CCPs), especially polythiophene, have been extensively used as probes for developing DNA and aptamer-based biosensors. Although many interesting applications have been achieved, a fundamental understanding of this system remains quite limited. In this work, we performed systematic binding assays to understand the interactions between poly(3-(3′-N,N,N-triethylamino-1′-propyloxy)-4-methyl-2,5-thiophene) (PMNT) and DNA. The fluorescence of PMNT at 530 nm initially decreased and then a peak at 580 nm emerged after binding with single-stranded DNA (ssDNA). The binding force between PMNT and DNA was dominated by electrostatic interactions at first and then DNA base-mediated interactions also became important. Since the bases in double-stranded DNA (dsDNA) were shielded, their fluorescence changes were quite different. To best differentiate ssDNA and dsDNA, the optimal pH was between 6 and 8, and the optimal NaCl concentration was around 0.3 M. Moreover, by changing the sequence and length of ssDNA, poly-T had the largest fluorescence shift and poly-A had the smallest change. Under the optimized conditions, the PMNT-based biosensor had a detection limit of 1 nM DNA, which was similar to the SYBR Green I-based assay.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.